Research Programs

Adheris conducts a variety of research programs systematically designed to study adherence to prescribed therapy. These research projects shed light on factors influencing medication adherence. They also help Adheris to develop and implement more targeted and customized educational programs to improve medication adherence.

Adheris collaborates on research projects with leading researchers in the area of adherence.

The Adheris Scientific Advisory Board provides input to all research programs based on the members' expertise in medical/health research and clinical practice. The research findings are published in peer-reviewed journals and presented at medical conferences.

For links to the current list of published research abstracts, click on the links below.

• The Effect of Transitioning to Medicare Part D Drug Coverage on Cardiac Medication Use In Seniors Dually Eligible for Medicare and Medicaid.
• Role of Patient Experience in Antidepressant Adherence: A Retrospective Data Analysis
• Analysis of Factors Associated With Statin Adherence in a Hierarchical Model Considering Physician, Pharmacy, Patient, and Prescription Characteristics
• Role of Patient Experience in Atypical Antipsychotic Adherence: A Retrospective Data Analysis
• Adherence and persistence with fluticasone propionate/salmeterol combination therapy
• The Role of Patient Medication Experience in Antidepressant Adherence
• Non Adherence with Oral Hypoglycemic Medications: Does Antidepressant Therapy Improve Adherence?
• Why Patients Stop Taking Medication?
• Impact of Population-based Adherence Programs on Improving Adherence to Venlafaxine Extended Release Therapy and Migration to a Different Product
• Impact of Population-based Adherence Programs on Improving Fluticasone / Salmeterol Inhalation Disc Use
• Noncompliance with Antihypertensive Medications: Does an Interdisiplinary Refill Reminder Program Make a Difference?
• Adherence to Oral Estrogen Replacement Therapy (ERT): Problem vs. Solution
• What Type of Patients Are at Higher Risk of Poor Compliance with Oral Hypoglycemic Agents
• Partial Adherence to Second Generation Antipsychotics